-
1
-
-
0020596734
-
Hamster preproglucagon contains the sequence of glucagon and two related peptides
-
1:CAS:528:DyaL3sXktFOnu74%3D 6835407 10.1038/302716a0
-
Bell GI, Santerre RF, Mullenbach GT (1983) Hamster preproglucagon contains the sequence of glucagon and two related peptides. Nature 302:716-718
-
(1983)
Nature
, vol.302
, pp. 716-718
-
-
Bell, G.I.1
Santerre, R.F.2
Mullenbach, G.T.3
-
2
-
-
79961191559
-
Regulation of glucagon secretion by incretins
-
1:CAS:528:DC%2BC3MXhtlaqsrjM 21824261 10.1111/j.1463-1326.2011.01452.x
-
Holst JJ, Christensen M, Lund A, et al. (2011) Regulation of glucagon secretion by incretins. Diabetes Obes Metab 13(Suppl 1):89-94
-
(2011)
Diabetes Obes Metab
, vol.13
, Issue.SUPPL. 1
, pp. 89-94
-
-
Holst, J.J.1
Christensen, M.2
Lund, A.3
-
3
-
-
0024028557
-
Effect of glicentin-related peptides upon the secretion of insulin and glucagon in the canine pancreas
-
1:CAS:528:DyaL1cXlt1alt7w%3D 3062845 10.1620/tjem.155.197
-
Ohneda A, Ohneda M (1988) Effect of glicentin-related peptides upon the secretion of insulin and glucagon in the canine pancreas. Tohoku J Exp Med 155:197-204
-
(1988)
Tohoku J Exp Med
, vol.155
, pp. 197-204
-
-
Ohneda, A.1
Ohneda, M.2
-
4
-
-
0029760864
-
Evidence for a major role for glucagon in regulation of plasma glucose in conscious, nondiabetic, and alloxan-induced diabetic rabbits
-
1:CAS:528:DyaK28XkslSis78%3D 8690155 10.2337/diab.45.8.1076
-
Brand CL, Jorgensen PN, Svendsen I, Holst JJ (1996) Evidence for a major role for glucagon in regulation of plasma glucose in conscious, nondiabetic, and alloxan-induced diabetic rabbits. Diabetes 45:1076-1083
-
(1996)
Diabetes
, vol.45
, pp. 1076-1083
-
-
Brand, C.L.1
Jorgensen, P.N.2
Svendsen, I.3
Holst, J.J.4
-
5
-
-
0014776021
-
Studies of pancreatic alpha cell function in normal and diabetic subjects
-
1:CAS:528:DyaE3cXhtlSgsr4%3D 322540 4986215 10.1172/JCI106297
-
Unger RH, Aguilar-Parada E, Muller WA, Eisentraut AM (1970) Studies of pancreatic alpha cell function in normal and diabetic subjects. J Clin Invest 49:837-848
-
(1970)
J Clin Invest
, vol.49
, pp. 837-848
-
-
Unger, R.H.1
Aguilar-Parada, E.2
Muller, W.A.3
Eisentraut, A.M.4
-
6
-
-
0034880691
-
Determinants of the effectiveness of glucagon-like peptide-1 in type 2 diabetes
-
1:CAS:528:DC%2BD3MXlvFeku70%3D 11502823 10.1210/jcem.86.8.7743
-
Toft-Nielsen MB, Madsbad S, Holst JJ (2001) Determinants of the effectiveness of glucagon-like peptide-1 in type 2 diabetes. J Clin Endocrinol Metab 86:3853-3860
-
(2001)
J Clin Endocrinol Metab
, vol.86
, pp. 3853-3860
-
-
Toft-Nielsen, M.B.1
Madsbad, S.2
Holst, J.J.3
-
7
-
-
84899062151
-
Early enhancements of hepatic and later of peripheral insulin sensitivity combined with increased postprandial insulin secretion contribute to improved glycemic control after Roux-en-Y gastric bypass
-
24241533 10.2337/db13-1307
-
Bojsen-Møller KN, Dirksen C, Jørgensen NB, et al. (2014) Early enhancements of hepatic and later of peripheral insulin sensitivity combined with increased postprandial insulin secretion contribute to improved glycemic control after Roux-en-Y gastric bypass. Diabetes 63:1725-1737
-
(2014)
Diabetes
, vol.63
, pp. 1725-1737
-
-
Bojsen-Møller, K.N.1
Dirksen, C.2
Jørgensen, N.B.3
-
8
-
-
84879189059
-
The effect of exogenous GLP-1 on food intake is lost in male truncally vagotomized subjects with pyloroplasty
-
1:CAS:528:DC%2BC3sXhtV2jurnK 23599045 10.1152/ajpgi.00035.2013
-
Plamboeck A, Veedfald S, Deacon CF, et al. (2013) The effect of exogenous GLP-1 on food intake is lost in male truncally vagotomized subjects with pyloroplasty. Am J Physiol Gastrointest Liver Physiol 304:G1117-G1127
-
(2013)
Am J Physiol Gastrointest Liver Physiol
, vol.304
-
-
Plamboeck, A.1
Veedfald, S.2
Deacon, C.F.3
-
9
-
-
84877040819
-
Gastrointestinal factors contribute to glucometabolic disturbances in nondiabetic patients with end-stage renal disease
-
1:CAS:528:DC%2BC3sXntVWqurs%3D 23325073 10.1038/ki.2012.460
-
Idorn T, Knop FK, Jorgensen M, Holst JJ, Hornum M, Feldt-Rasmussen B (2013) Gastrointestinal factors contribute to glucometabolic disturbances in nondiabetic patients with end-stage renal disease. Kidney Int 83:915-923
-
(2013)
Kidney Int
, vol.83
, pp. 915-923
-
-
Idorn, T.1
Knop, F.K.2
Jorgensen, M.3
Holst, J.J.4
Hornum, M.5
Feldt-Rasmussen, B.6
-
10
-
-
0020456354
-
Evidence that enteroglucagon (II) is identical with the C-terminal sequence (residues 33-69) of glicentin
-
1:CAS:528:DyaL3sXhvFWru7g%3D 1153876 7165698
-
Holst JJ (1982) Evidence that enteroglucagon (II) is identical with the C-terminal sequence (residues 33-69) of glicentin. Biochem J 207:381-388
-
(1982)
Biochem J
, vol.207
, pp. 381-388
-
-
Holst, J.J.1
-
11
-
-
0022531614
-
Glicentin 1-61 probably represents a major fraction of glucagon-related peptides in plasma of anaesthetized uraemic pigs
-
1:CAS:528:DyaL28Xls1Gmsrg%3D 3743926 10.1007/BF00506540
-
Baldissera FG, Holst JJ (1986) Glicentin 1-61 probably represents a major fraction of glucagon-related peptides in plasma of anaesthetized uraemic pigs. Diabetologia 29:462-467
-
(1986)
Diabetologia
, vol.29
, pp. 462-467
-
-
Baldissera, F.G.1
Holst, J.J.2
-
12
-
-
4143138571
-
Neutral endopeptidase 24.11 is important for the degradation of both endogenous and exogenous glucagon in anesthetized pigs
-
1:CAS:528:DC%2BD2cXnvVejtbk%3D 15126240 10.1152/ajpendo.00353.2003
-
Trebbien R, Klarskov L, Olesen M, Holst JJ, Carr RD, Deacon CF (2004) Neutral endopeptidase 24.11 is important for the degradation of both endogenous and exogenous glucagon in anesthetized pigs. Am J Physiol Endocrinol Metab 287:E431-E438
-
(2004)
Am J Physiol Endocrinol Metab
, vol.287
-
-
Trebbien, R.1
Klarskov, L.2
Olesen, M.3
Holst, J.J.4
Carr, R.D.5
Deacon, C.F.6
-
13
-
-
84899492680
-
Specificity and sensitivity of commercially available assays for glucagon and oxyntomodulin measurement in humans
-
1:CAS:528:DC%2BC2cXntVeisLY%3D 24412928 10.1530/EJE-13-0941
-
Bak MJ, Albrechtsen NW, Pedersen J, et al. (2014) Specificity and sensitivity of commercially available assays for glucagon and oxyntomodulin measurement in humans. Eur J Endocrinol 170:529-538
-
(2014)
Eur J Endocrinol
, vol.170
, pp. 529-538
-
-
Bak, M.J.1
Albrechtsen, N.W.2
Pedersen, J.3
-
14
-
-
0018946923
-
Evidence that glicentin contains the entire sequence of glucagon
-
1:CAS:528:DyaL3cXltV2hsLs%3D 1161798 6893148
-
Holst JJ (1980) Evidence that glicentin contains the entire sequence of glucagon. Biochem J 187:337-343
-
(1980)
Biochem J
, vol.187
, pp. 337-343
-
-
Holst, J.J.1
-
15
-
-
84905582556
-
Effect of aprotinin (Trasylol™) on degradation of exogenous and endogenous glucagon in human, mouse and rat plasma
-
Bak MJ, Albrechtsen NW, Hartmann B, et al. (2014) Effect of aprotinin (Trasylol™) on degradation of exogenous and endogenous glucagon in human, mouse and rat plasma. J Endocrinol Diabetes 1:5
-
(2014)
J Endocrinol Diabetes
, vol.1
, pp. 5
-
-
Bak, M.J.1
Albrechtsen, N.W.2
Hartmann, B.3
-
16
-
-
79959781838
-
Loss of incretin effect is a specific, important, and early characteristic of type 2 diabetes
-
1:CAS:528:DC%2BC3MXntlKksL0%3D 3632188 21525464 10.2337/dc11-s227
-
Holst JJ, Knop FK, Vilsboll T, Krarup T, Madsbad S (2011) Loss of incretin effect is a specific, important, and early characteristic of type 2 diabetes. Diabetes Care 34:S251-S257
-
(2011)
Diabetes Care
, vol.34
-
-
Holst, J.J.1
Knop, F.K.2
Vilsboll, T.3
Krarup, T.4
Madsbad, S.5
-
17
-
-
0021058005
-
Circulating glucagon after total pancreatectomy in man
-
1:CAS:528:DyaL2cXmt1anuw%3D%3D 6653943 10.1007/BF00282517
-
Holst JJ, Pedersen JH, Baldissera F, Stadil F (1983) Circulating glucagon after total pancreatectomy in man. Diabetologia 25:396-399
-
(1983)
Diabetologia
, vol.25
, pp. 396-399
-
-
Holst, J.J.1
Pedersen, J.H.2
Baldissera, F.3
Stadil, F.4
-
18
-
-
0020625966
-
Gut glucagon, enteroglucagon, gut glucagonlike immunoreactivity, glicentin - Current status
-
1:CAS:528:DyaL3sXktFKlsr4%3D 6188645
-
Holst JJ (1983) Gut glucagon, enteroglucagon, gut glucagonlike immunoreactivity, glicentin - current status. Gastroenterology 84:1602-1613
-
(1983)
Gastroenterology
, vol.84
, pp. 1602-1613
-
-
Holst, J.J.1
-
19
-
-
79955153811
-
Diminished glucagon suppression after β-cell reduction is due to impaired α-cell function rather than an expansion of α-cell mass
-
1:CAS:528:DC%2BC3MXlt1OrsbY%3D 3279300 21285404 10.1152/ajpendo.00315. 2010
-
Meier JJ, Ueberberg S, Korbas S, Schneider S (2011) Diminished glucagon suppression after β-cell reduction is due to impaired α-cell function rather than an expansion of α-cell mass. Am J Physiol Endocrinol Metab 300:E717-E723
-
(2011)
Am J Physiol Endocrinol Metab
, vol.300
-
-
Meier, J.J.1
Ueberberg, S.2
Korbas, S.3
Schneider, S.4
-
21
-
-
0041464620
-
Differential regional metabolism of glucagon in anesthetized pigs
-
1:CAS:528:DC%2BD3sXnsVGmt7c%3D 12759222
-
Deacon CF, Kelstrup M, Trebbien R, Klarskov L, Olesen M, Holst JJ (2003) Differential regional metabolism of glucagon in anesthetized pigs. Am J Physiol Endocrinol Metab 285:E552-E560
-
(2003)
Am J Physiol Endocrinol Metab
, vol.285
-
-
Deacon, C.F.1
Kelstrup, M.2
Trebbien, R.3
Klarskov, L.4
Olesen, M.5
Holst, J.J.6
-
22
-
-
84880949323
-
Characterisation of oral and i.V. Glucose handling in truncally vagotomised subjects with pyloroplasty
-
1:CAS:528:DC%2BC3sXhtlCrsr3E 3709640 23704713 10.1530/EJE-13-0264
-
Plamboeck A, Veedfald S, Deacon CF, et al. (2013) Characterisation of oral and i.v. glucose handling in truncally vagotomised subjects with pyloroplasty. Eur J Endocrinol 169:187-201
-
(2013)
Eur J Endocrinol
, vol.169
, pp. 187-201
-
-
Plamboeck, A.1
Veedfald, S.2
Deacon, C.F.3
-
23
-
-
0038574573
-
Gastric inhibitory polypeptide (GIP) dose-dependently stimulates glucagon secretion in healthy human subjects at euglycaemia
-
1:CAS:528:DC%2BD3sXkvFyjtrk%3D 12764578 10.1007/s00125-003-1103-y
-
Meier JJ, Gallwitz B, Siepmann N, et al. (2003) Gastric inhibitory polypeptide (GIP) dose-dependently stimulates glucagon secretion in healthy human subjects at euglycaemia. Diabetologia 46:798-801
-
(2003)
Diabetologia
, vol.46
, pp. 798-801
-
-
Meier, J.J.1
Gallwitz, B.2
Siepmann, N.3
-
24
-
-
84893065360
-
Contribution of endogenous glucagon-like peptide 1 to glucose metabolism after Roux-en-Y gastric bypass
-
1:CAS:528:DC%2BC2cXhvVSku7w%3D 24089513 10.2337/db13-0954
-
Shah M, Law JH, Micheletto F, et al. (2014) Contribution of endogenous glucagon-like peptide 1 to glucose metabolism after Roux-en-Y gastric bypass. Diabetes 63:483-493
-
(2014)
Diabetes
, vol.63
, pp. 483-493
-
-
Shah, M.1
Law, J.H.2
Micheletto, F.3
|